No Data
Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
RBC Downgrades Applied Therapeutics as FDA Rejects Govorestat, Hacks Price Target
Express News | Applied Therapeutics Shares Are Trading Lower After the Company Announced the FDA Highlighted Deficiencies in a Clinical Application for a Lead Program
RBC Capital Initiates Applied Therapeutics(APLT.US) With Hold Rating, Announces Target Price $12
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of US Farm Prices Data
Top Premarket Decliners
No Data
No Data
